Application of artemisinin compound in treatment of coronavirus infection

Technology of a compound, artemisinin, applied in the field of biomedicine

Pending Publication Date: 2020-10-23
ACADEMY OF MILITARY MEDICAL SCI
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, for the new coronavirus infection, supportive treatment is

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of artemisinin compound in treatment of coronavirus infection
  • Application of artemisinin compound in treatment of coronavirus infection
  • Application of artemisinin compound in treatment of coronavirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0134] Example 1: Artemisinin reduces the virus nucleic acid load experiment of SARS-CoV-2 infected cells

[0135] (1) Drug treatment of virus-infected cells

[0136] Inoculate Vero E6 cells (purchased from ATCC, Cat. No. 1586) into 24-well plates and culture for 24 hours; then carry out virus infection, specifically, with 2% cell maintenance solution (formulation: FBS (purchased from Gibco, Cat. No. 16000044) Add MEM (purchased from Gibco, product number 10370021) according to the volume ratio of 2%, which is 2% cell maintenance solution) SARS-CoV-2 (2019-nCoV) virus (nCoV-2019BetaCoV / Wuhan / WIV04 / 2019 strain, Provided by the Wuhan Institute of Virology, Chinese Academy of Sciences) diluted to the corresponding concentration, and then added to a 24-well plate so that each well contains 100 TCID of virus 50. Next, dilute artemisinin (purchased from Selleck Chemicals, product number S1282) to corresponding concentrations with 2% cell maintenance solution, and add to correspond...

Embodiment 2

[0175] Example 2: Artemisinin reduces the virus nucleic acid load experiment of SARS-CoV-2 infected cells

[0176] (1) Drug treatment of virus-infected cells

[0177] Inoculate Vero E6 cells (purchased from ATCC, Cat. No. 1586) into 24-well plates and culture for 24 hours; then carry out virus infection, specifically, with 2% cell maintenance solution (formulation: FBS (purchased from Gibco, Cat. No. 16000044) Add MEM (purchased from Gibco, product number 10370021) according to the volume ratio of 2%, which is 2% cell maintenance solution) SARS-CoV-2 (2019-nCoV) virus (nCoV-2019BetaCoV / Wuhan / WIV04 / 2019 strain, Provided by the Wuhan Institute of Virology, Chinese Academy of Sciences) diluted to the corresponding concentration, and then added to a 24-well plate so that each well contains 100 TCID of virus 50 . Next, artemisinin (purchased from MCE, product number HY-N2016) was diluted to corresponding concentrations with 2% cell maintenance solution, and added to corresponding...

Embodiment 3

[0216] Example 3: Artemether reduces the virus nucleic acid load experiment of SARS-CoV-2 infected cells

[0217] (1) Drug treatment of virus-infected cells

[0218] Inoculate Vero E6 cells (purchased from ATCC, Cat. No. 1586) into 24-well plates and culture for 24 hours; then carry out virus infection, specifically, with 2% cell maintenance solution (formulation: FBS (purchased from Gibco, Cat. No. 16000044) Add MEM (purchased from Gibco, product number 10370021) according to the volume ratio of 2%, which is 2% cell maintenance solution) SARS-CoV-2 (2019-nCoV) virus (nCoV-2019BetaCoV / Wuhan / WIV04 / 2019 strain, Provided by the Wuhan Institute of Virology, Chinese Academy of Sciences) diluted to the corresponding concentration, and then added to a 24-well plate so that each well contains 100 TCID of virus 50 . Next, artemether (purchased from Selleck Chemicals, product number S3889) was diluted to corresponding concentrations with 2% cell maintenance solution, and added to the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of an artemisinin compound in treatment of coronavirus infection. Specifically, the invention provides application of the compound, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of medicines. The medicines are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2), and thecompound is selected from one or more of artemisinin, arteether, artemether, artemisinin, dihydroartemisinin, artesunate, artemisinin B and arteannuic acid.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of artemisinin compounds in the treatment of coronavirus infection. Background technique [0002] Artemisinin is a semiterpene lactone compound extracted by Chinese scientists from Artemisia annua of Compositae. Artemisinin-related compounds (compounds of formula I) are a general term for a class of compounds that are similar in structure to artemisinin or form a compound, including Artether, artemether, artemisinin, dihydroartemisinin, artesunate, artemisinin, artemisinic acid and other compounds. Artemisinin and its derivatives are currently one of the most effective drugs to treat malaria in the world, and artemisinin combination therapy has been widely used all over the world. Among artemisinin-related compounds, dihydroartemisinin, artemether, artesunate, and artether have all been marketed as antimalarial drugs. In addition, other derivatives such as artemisinin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/366A61K31/357A61K31/541A61K31/365A61K31/19A61K31/137A61P31/14A61P11/00
CPCA61K31/366A61K31/357A61K31/541A61K31/365A61K31/19A61K31/137A61P31/14A61P11/00A61K2300/00
Inventor 曹瑞源王曼丽李薇赵磊杨晶晶李月香樊士勇周辛波肖典胡志红李松钟武
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap